Month: November 2022

On August 17, 2006, Beard, Charles D.; Lee, Ving J.; Whittle, C. Ed published a patent.Related Products of 89792-07-4 The title of the patent was Process for the preparation of aza-annelated pyrroles, thiophenes and furans as potential bioisosteres of indole, benzofuran and benzothiophene scaffolds. And the patent contained the following:

A process for the preparation of aza-annelated pyrroles, thiophenes and furans I [wherein T = (un)substituted NH, O or S; R2 = H, (halo)alkyl, (un)substituted aryl, etc.; W, X, Y, Z = (un)substituted CH or N with limitations; D = H or Br], which are potentially useful as bioisosteres of indole, benzofuran and benzothiophene scaffolds, is disclosed. The process comprises coupling iodides II with acetylene compounds CHCCH2R2 or silyl group-protected acetylene such as CHC-TMS, and cyclizing the resultant alkynes in protic solvents. Key features of the method include regioselective substitution in the iodine sites and tolerance of a wide range of sensitive functional groups. For instance, regioselective Sonogashira reaction of 5-bromo-3-iodo-2-pyridinamine (preparation given) with CHC-TMS in toluene in the presence of PdCl2(PPh3)2, CuI and Et3N gave ethynylpyridinamine III in 80% yield. This compound underwent t-BuOK-mediated intramol. cyclization in refluxing t-butanol to afford 5-bromo-1H-pyrrolo[2,3-b]pyridine in 60% yield. The experimental process involved the reaction of 2-Methyl-7H-pyrrolo[2,3-d]pyrimidine(cas: 89792-07-4).Related Products of 89792-07-4

The Article related to iodopyridinamine preparation acetylene palladium copper sonogashira coupling, ethynylpyridinamine preparation intramol cyclization, pyrrolopyridine azaindole preparation, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Related Products of 89792-07-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On June 28, 2019, Portalone, Gustavo published an article.Application of 626-48-2 The title of the article was 6-Methyluracil: a redetermination of polymorph (II). And the article contained the following:

6-Methyluracil, C5H6N2O2, exists in two crystalline phases: form (I), monoclinic, space group P21/c [Reck et al. (1988). Acta Crystalline A44, 417-421] and form (II), monoclinic, space group C2/c [Leonidov et al. (1993). Russ. J. Phys. Chem.67, 2220-2223]. The structure of polymorph (II) has been redetermined providing a significant increase in the precision of the derived geometric parameters. In the crystal, mols. form ribbons approx. running parallel to the c-axis direction through N-H···O hydrogen bonds. The radical differences observed between the crystal packing of the two polymorphs may be responsible in form (II) for an increase in the contribution of the polar canonical forms C-(O-)=N-H+ relative to the neutral canonical form C(=O)-N-H induced by hydrogen-bonding interactions. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Application of 626-48-2

The Article related to methyluracil polymorph redetn hydrogen bond crystal structure, Crystallography and Liquid Crystals: Crystallization and Recrystallization, Nucleation, Crystal Growth, Epitaxy, Nonepitaxial Film Deposition and other aspects.Application of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 12, 2003, Cadilla, Rodolfo; Henke, Brad Richard; Lambert, Millard H., III; Liu, Guangcheng Kevin; Smith, Jennifer Susan published a patent.Safety of 2-Chloro-5-isopropylpyrimidine The title of the patent was Preparation of phenoxyalkanoic acid derivatives as hPPAR activators for treatment of diabetes and cardiovascular diseases. And the patent contained the following:

Title compounds I [wherein R1 and R2 = independently H, F, CF3, or alkyl; or CR1R2 = cycloalkyl; R3 = (un)substituted heteroaryl; R4 and R5 = independently H, (perfluoro)alkyl, (perfluoro)alkoxy, halo, or CN; R6 = (un)substituted Ph or heteroaryl; R7 and R8 = independently H, F, CF3, or alkyl with the proviso that the C to which R7 and R8 are bonded is either meta or para to the depicted O; m and n = independently 1-2; or pharmaceutically acceptable salts, solvates, acid isosteres, or hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators (no data). For example, Me 2-[4-[2-[[2,4-bis(trifluoromethyl)benzyl]amino]ethyl]phenoxy]-2-methylpropanoate was coupled with 2-chloro-5-ethylpyrimidine using DIEA in toluene to give the tertiary amine (38%). Hydrolysis of the ester with NaOH provided II (48%). Methods for treating diseases or conditions associated with hPPARα, hPPARγ, or hPPARδ, such as diabetes and cardiovascular diseases, comprising administration of a therapeutically effective amount of I or a pharmaceutical composition comprising I are also disclosed (no data). The experimental process involved the reaction of 2-Chloro-5-isopropylpyrimidine(cas: 596114-50-0).Safety of 2-Chloro-5-isopropylpyrimidine

The Article related to phenoxyalkanoic acid preparation ppar activator antidiabetic cardiovascular agent, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Carboxylic Acids and Peroxycarboxylic Acids and Their Sulfur-Containing Analogs and Salts and other aspects.Safety of 2-Chloro-5-isopropylpyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 31, 2017, Ostakhov, S. S.; Sultanbaev, M. V.; Ovchinnikov, M. Yu.; Kayumov, R. R.; Khursan, S. L. published an article.COA of Formula: C5H6N2O2 The title of the article was Spectral-luminescence and quantum-chemical study of the anionic forms of 5-fluorouracil. And the article contained the following:

A spectral-luminescence study of neutral (pH 7) and alk. (pH 11 and 14) aqueous solutions of the anticancer drugs 5-fluorouracil (FU) and tegafur has been performed. The fluorescence spectra of the N3- and N1-centered anions of 5-fluorouracil, its dianion, and the tegafur monoanion with emission maxima at wavelengths (λem) of 358, 372, 366, and 358 nm and photoluminescence quantum yields (φ) of 11.2 x 10-4, 35.1 x 10-4, 26.5 x 10-4, and 8.6 x 10-4, resp., have been recorded for the first time. The fluorescence characteristics of the FU anionic forms have been related to the magnetic shielding constant as one of the criteria of aromaticity. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).COA of Formula: C5H6N2O2

The Article related to fluorouracil tegafur uv fluorescence spectra ph effect, Physical Organic Chemistry: Absorption, Emission, Reflection, and Scattering Spectra (Ultraviolet and Visible, Infrared and Fourier Transform Infrared, Raman, Microwave, Photoelectron, Fluorescence, Phosphorescence, etc.) and other aspects.COA of Formula: C5H6N2O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Grosmaire, L.; Delarbre, J.-L. published an article in 2012, the title of the article was Vibrational spectra of 6-methyluracil, 6-methyl-2-thiouracil and their deuterated analogues.Name: 6-Methylpyrimidine-2,4(1H,3H)-dione And the article contains the following content:

FTIR and Raman spectra of 6-methyluracil (6MU), 6-methyl-2-thiouracil (6M2TU) and the deuterated forms were recorded and analyzed in the regions 400-4000 cm-1 and 100-4000 cm-1, resp. The vibrational spectra are assigned using the frequency shifts upon N-deuteration, especially for bands due to NH modes. For both mols., the isotopic ratio frequency was calculated for each NH/ND vibrations. The sulfur substitution at C2 position in the 6MU mol. has an effect on the N1H and N3H vibrational frequencies. The assignments of C2=O and C4=O modes were supported by the absence of the C2=O group in the thio-derivative The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Name: 6-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to vibrational spectra methyluracil methylthiouracil deuterated analog, Physical Organic Chemistry: Absorption, Emission, Reflection, and Scattering Spectra (Ultraviolet and Visible, Infrared and Fourier Transform Infrared, Raman, Microwave, Photoelectron, Fluorescence, Phosphorescence, etc.) and other aspects.Name: 6-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 3, 2014, Sasidharanpillai, Swaroop; Loppnow, Glen R. published an article.HPLC of Formula: 626-48-2 The title of the article was Initial Excited-State Structural Dynamics of 5,6-Dimethyluracil from Resonance Raman Spectroscopy. And the article contained the following:

In order to understand the effect of Me substitution patterns on the initial excited-state structural dynamics of uracil derivatives, we measured the resonance Raman spectra of 5,6-dimethyluracil (5,6-DMU). The results show that the resonance Raman spectrum is a combination of that of 5-methyl- and 6-methyluracil. The resonance Raman excitation profiles (RREPs) and absorption spectrum are simulated with a self-consistent, time-dependent formalism to yield the excited-state slopes and broadening parameters. The initial excited-state structural dynamics occur primarily along the C5=C6 stretching mode, as expected, but with lesser excited-state slopes along each mode compared to 5-methyluracil and 6-methyluracil. This study along with previous experiments with different uracil derivatives show that the presence and positions of the Me groups seems to determine the partitioning of initial excited-state structural dynamics. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).HPLC of Formula: 626-48-2

The Article related to excited state structural dynamics dimethyluracil resonance raman spectra, Physical Organic Chemistry: Absorption, Emission, Reflection, and Scattering Spectra (Ultraviolet and Visible, Infrared and Fourier Transform Infrared, Raman, Microwave, Photoelectron, Fluorescence, Phosphorescence, etc.) and other aspects.HPLC of Formula: 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 31, 2013, Manivannan, C.; Sambathkumar, S.; Renganathan, R. published an article.Synthetic Route of 626-48-2 The title of the article was Interaction of acriflavine with pyrimidines: A spectroscopic approach. And the article contained the following:

The interaction of acriflavine with uracils was studied by using spectroscopic tools viz., UV-visible absorption, steady state and time resolved fluorescence measurements. The spectroscopic data were analyzed using Stern-Volmer equation to determine the quenching process. The bimol. quenching rate constant (kq), binding constant (K) and number of binding sites (n) were calculated at different temperature from the relevant fluorescence data. The exptl. results obtained from life-time measurement indicate that the quenching mechanism was static via the formation of ground state complex. The free energy change (ΔGet) for electron transfer process was calculated by Rehm-Weller equation. The existence of binding forces and the interactions of acriflavine with uracils were examined The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Synthetic Route of 626-48-2

The Article related to acriflavine pyrimidine spectroscopic, acriflavine, fluorescence quenching, uracils, Physical Organic Chemistry: Absorption, Emission, Reflection, and Scattering Spectra (Ultraviolet and Visible, Infrared and Fourier Transform Infrared, Raman, Microwave, Photoelectron, Fluorescence, Phosphorescence, etc.) and other aspects.Synthetic Route of 626-48-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 31, 2020, Yin, Yuan; Chen, Cheng-Juan; Yu, Ru-Nan; Shu, Lei; Wang, Zhi-Jian; Zhang, Tian-Tai; Zhang, Da-Yong published an article.Synthetic Route of 4433-40-3 The title of the article was Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis. And the article contained the following:

Selective JAK3 inhibitors have been shown to have a potential benefit in the treatment of autoimmune disorders. Here we report the identification of a series of pyrazolopyrimidine derivatives as potent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Most of these compounds (13k, 13n and 13 t), displayed stronger anti-JAK3 kinase activity and selectivity than tofacitinib. Furthermore, the most active inhibitor 13t (IC50 = 0.1 nM), also exhibited favorable selectivity for JAK3 in a panel of 9 kinases which contain the same cysteine. In a series of cytokine-stimulated cellular anal., compound 13 t, could potently block the JAK3-STAT signaling pathway. Further biol. studies, including cellular antiproliferative activity assays and a rat adjuvant-induced arthritis model for in vivo evaluation, also indicated its efficacy and low toxicity in the treatment of rheumatoid arthritis. The results of these exptl. explorations suggested that 13t is a promising lead compound for the development of selective JAK3 inhibitor with therapeutic potential in rheumatoid arthritis. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Synthetic Route of 4433-40-3

The Article related to pyrazolo pyrimidin amino derivative preparation jak3 inhibitor rheumatoid arthritis, 4-d]pyrimidin, autoimmune diseases, jak3 inhibitors, pyrazolo[3, rheumatoid arthritis and other aspects.Synthetic Route of 4433-40-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 5, 2016, Ruehter, Gerd; Koch, Uwe; Nussbaumer, Peter; Schulz-Fademrecht, Carsten; Eickhoff, Jan published a patent.Application of 1187830-46-1 The title of the patent was Pharmaceutically active disubstituted triazine derivatives. And the patent contained the following:

The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunol. diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase. The experimental process involved the reaction of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride(cas: 1187830-46-1).Application of 1187830-46-1

The Article related to triazine derivative infection immune autoimmune cardiovascular proliferation disease preparation, erectile dysfunction stroke triazine derivative protein kinase inhibitor and other aspects.Application of 1187830-46-1

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 7, 2012, Ruehter, Gerd; Koch, Uwe; Nussbaumer, Peter; Schultz-Fademrecht, Carsten; Eickhoff, Jan published a patent.Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride The title of the patent was Pharmaceutically active disubstituted triazine derivatives. And the patent contained the following:

The invention discloses disubstituted triazine derivatives and/or pharmaceutically acceptable salts and the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunol. diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts,. Furthermore, the invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase and the preparation of said compounds The experimental process involved the reaction of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride(cas: 1187830-46-1).Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride

The Article related to triazine derivative infection immune autoimmune cardiovascular proliferation disease preparation, erectile dysfunction stroke triazine derivative protein kinase inhibitor and other aspects.Reference of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia